Community oncologists say the drug-price control recommendations by 118 cancer doctors that made national headlines last week are misguided because most of the doctors behind the suggestions work for large, teaching hospitals where cancer care is more expensive than at cancer clinics. Drug makers also criticized the recommendations for singling out drug prices, which account for about a quarter of cancer treatments and 1 percent of health care spending overall, and the Pharmaceutical Research and Manufacturers of America highlighted the...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.